Risk of Liver Fibrosis in Methotrexate-Treated Patients: A Systematic Review

Methotrexate (MTX), an antifolate agent, is recommended as the first-line disease-modifying antirheumatic drug (DMARD). In this systematic review, our goals were to assess liver fibrosis in methotrexate-treated patients, evaluate liver fibrosis in relation to treatment duration and cumulative dose,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bichenapally, Sumahitha, Khachatryan, Vahe, Muazzam, Asmaa, Hamal, Chandani, Velugoti, Lakshmi Sai Deepak Reddy, Tabowei, Godfrey, Gaddipati, Greeshma N, Mukhtar, Maria, Alzubaidee, Mohammed J, Dwarampudi, Raga Sruthi, Mathew, Sheena, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711916/
https://www.ncbi.nlm.nih.gov/pubmed/36465792
http://dx.doi.org/10.7759/cureus.30910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711916/
https://www.ncbi.nlm.nih.gov/pubmed/36465792
http://dx.doi.org/10.7759/cureus.30910

Ejemplares similares